Synthesis and in vitro activity of various derivatives of a novel thromboxane receptor antagonist, (.+-.)-(5Z)-7-[3-endo[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-exo-yl]heptenoic acid

Abstract

Several sulfonyl derivatives (13a-t) of (.+-.)-(5Z)-7-(3-endo-aminobicyclo[2.2.1]hept-2-exo-yl)heptenoic acid (VI) were synthesized via its methyl ester 10. Sulfonylation of 10 with 11a-t followed by saponificatin yielded 13a-t. Inhibitory concentrations (IC50) of the corresponding sodium salts 14a-t for platelet aggregation were measured with rat washed platelets (WP) and rabbit-rich plasma (PRP). IC50 values of some derivatives for contraction of the rat aorta were also measured. The IC50 values for rat WP increased from 2.9 nM in the order of 14a, 14c, 14d, and 14b for derivatives with an arylsulfonyl residue, depending on the number of intervening methylene groups. Methyl derivative 14e exhibited a higher IC50 value than n-hexyl derivative 14f. Substitution with a p-methyl, p-fluoro-or p-chloro group in 14a retained or slightly reduced its IC50 value, while a p-n-pentyl or p-oxycarbonyl group augmented it significantly. The representative 14a suppressed (15S)-15-hydroxy-11.9-(epoxymethano)prosta-5(Z),13(E)-dienoic acid (U-46619) induced aggregation of human WP with an IC50 value of 7.7 mM, which corresponds well to the IC50 value of 3 mM obtained for each displacement by 14a of [3H]-U-46619 or (5Z,15.zeta.)-9.alpha.,11.alpha.-(dimethylmethano)-15-hydroxy-16-(3-[125I]iodo-4-hydroxyphenyl)-17,18,19,20-tetranor-13-aza-11a-carbathrombo-5-enoic acid ([125I]-PTA-OH) bound to human WP. Synthesis of thromboxane A2 (TxA2) in human WP stimulated by thrombin was not inhibited by 14a at a concentration up to 10 .mu.M. From these observations, the corresponding acid 13a (S-145) was concludedto be a potent TxA2 receptor antagonist.